Hoth Therapeutics Expands HT-001 Trial Enrollment with New Site, Reflecting Growing Demand for Cancer Treatment

Hoth Therapeutics has accelerated HT-001 trial enrollment with the addition of Regis Clinical Research as a new site, reflecting surging patient demand for the first-in-class therapy for cancer patients with no current FDA-approved treatment option. The CLEER-001 Phase 2a trial has shown positive results, with 100% of patients achieving the primary efficacy endpoint and zero dose-limiting toxicities observed. The expansion of the trial network is expected to lead to faster enrollment and a faster path to regulatory milestones.